Gregoriadis G
Centre for Drug Delivery Research, School of Pharmacy, University of London, 29-39 Brunswick Square, London, WCIN 1AX, UK.
Curr Opin Mol Ther. 1999 Feb;1(1):39-42.
Vaccination with attenuated or killed microbes, purified or recombinant subunit proteins and synthetic peptides is often hampered by toxicity, the presence of infectious agents, weak immune responses and prohibiting costs, especially in the developing world. Such problems may be circumvented by genetic immunization, which, by the use of plasmid DNA encoding antigens from bacteria, viruses, protozoa and cancers leads to protective humoral and cell-mediated immunity. This review deals with the background and progress made so far with DNA vaccines and evaluates the role of liposomes in their optimization.
用减毒或灭活微生物、纯化或重组亚单位蛋白以及合成肽进行疫苗接种，常常受到毒性、感染因子的存在、免疫反应微弱以及成本高昂的阻碍，尤其是在发展中世界。基因免疫可以规避这些问题，通过使用编码来自细菌、病毒、原生动物和癌症的抗原的质粒DNA，可产生保护性体液免疫和细胞介导免疫。本文综述了DNA疫苗的背景和迄今取得的进展，并评估了脂质体在优化DNA疫苗方面的作用。
